VFY.AU Vitrafy Life Sciences Ltd
- Market cap
- AUD 173M
- P/E
- -
- P/B
- 4.21x
- ROE
- -39.3%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is VFY.AU undervalued?
Graham numberThe Graham number of Vitrafy Life Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vitrafy Life Sciences Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-39.3%), below 10%.
ROA 0/1
Return on assets (-37.4%) is below the industry median (-23.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (58.1%) is above the industry median (18.8%).
Revenue Growth 2/2
Revenue grew 74.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.2x) is above the industry median (3.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Vitrafy Life Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vitrafy Life Sciences Ltd
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various app…
Full company profileVitrafy Life Sciences Ltd financial statements
Vitrafy Life Sciences Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | 32.0K | 37.0K | 65.1K | 169K |
| Gross Profit | - | 32.0K | 37.0K | 65.1K | 169K |
| Operating Income | -6.44M | -9.17M | -10.7M | -16.6M | -20.4M |
| EBITDA | - | -2.82M | 7.00K | -26.1M | -16.0M |
| Net Income | -7.66M | -7.81M | -10.4M | -32.7M | -16.2M |
| EPS | -0.12 | -0.12 | -0.16 | -0.51 | -0.21 |
| Balance Sheet | |||||
| Total Assets | 0.00 | 0.00 | 41.3M | 31.8M | 43.2M |
| Total Liabilities | 0.00 | 0.00 | 1.34M | 3.08M | 2.10M |
| Shareholders' Equity | 0.00 | 0.00 | 40.0M | 28.8M | 41.1M |
| Cash & Short-term Investments | - | - | 38.0M | 19.5M | 26.1M |
| Cash Flow | |||||
| Capital Expenditure | 486K | 90.0K | 13.0K | 1.85K | 537K |
| Free Cash Flow | -6.36M | -5.05M | -6.80M | -8.80M | -16.3M |
| Ratios | |||||
| ROE | - | - | -26.1% | -113.7% | -39.3% |
| ROA | - | - | -25.2% | -102.7% | -37.4% |
| Net Profit Margin | - | -24,415.6% | -28,175.7% | -50,237.2% | -9,584.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vitrafy Life Sciences Ltd dividends
Vitrafy Life Sciences Ltd has not paid dividends in the last 5 fiscal years.
Who owns Vitrafy Life Sciences Ltd
- Insiders 45.13%
- Institutions 2.27%
- Public & others 52.60%
- Shares outstanding 76.2M
- Free float 50.6M
Vitrafy Life Sciences Ltd company profile
- Company name
- Vitrafy Life Sciences Ltd
- Ticker
- VFY.AU
- Exchange
- Australian Securities Exchange
- Sector
- Technology
- Industry
- Software - Infrastructure
- Fiscal year end
- June
- Address
- 385 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9692 7222
- Website
- vitrafy.com
About Vitrafy Life Sciences Ltd
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
Vitrafy Life Sciences Ltd management
4- Mr. Brenton Michael Leslie OwensCo-Founder, MD, CEO & Executive Director
- Mr. Simon Thomas MartinChief Financial Officer
- Dr. Heather PidcokeChief Science Officer
- Mr. Michael Sapountzis AGIA, B.Com., L.L.B., M.A.I.C.D.Company Secretary